5Miyahara C,Miyazawa M,Satoh S,et al.Inhibitor effects of mulberryleaf extract on postprandial hyper-glycemiain normalrats[J].J Nutr Sci Vitaminol,2004,5(3):161-164.
6National Kidney Foundation.K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney diease[J].Am J Kidney Dis,2003,41(Suppl 4):S1-S92.
7Weisman SM,Graham DY.Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events[J].Arch Intern Med,2002,162(19):2197-2202.
8Cachofeiro V,Goicochea M,de Vinuesa SG,et al.Oxidative stress and inflammation,a link between chronic kidney disease and cardiovascular disease[J].Kidney Int,2008,111(Suppl):S4-S9.
3VirzìGM,Clementi A,de Cal M,et al.Oxidative stress:dual pathway induction in cardiorenal syndrome type 1 pathogenesis[J].Oxid Med Cell Longev,2015,2015:391790.
4VirzìG,Day S,de Cal M,et al.Heart-kidney Crosstalk and role of humoral signaling in criticalillness[J].Crit Care,2014,18(1):201.
5House AA.Cardio-renal syndrome type 4:epidemiology,pathophysiology and treatment[J].Semin Nephrol,2012,32(1):40-8.
6Kingma JG,Simard D,Rouleau JR.Renocardiacsyndromes:physi opathology and treatment stratagems[J].Can J Kidney Health Dis,2015(2):41.
7Ronco C,Ronco F.Cardio-renal syndromes:a systematic approach for consensus definition and classification[J].Heart Fail Rev,2012,17(2):151-160.
8Michael Haase,Christian Muller,Kevin Damman,et al.Pathogenesis of cardiorenal syndrome type1 in acute decompensated heartfailure:workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative(ADQI)[J].Contrib Nephrol,2013(182):99-116.
9Damman K1,van Deursen VM,Navis G,et al.Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease[J].J Am Coll Cardiol,2009,53(7):582-8.
10Uthoff H1,Breidthardt T,Klima T,et al.Central venous pressure and impaired renal function in patients with acute heart failure[J].Eur J Heart Fail,2011,13(4):432-9.